Alkermes Plc (ALKS) 71.40 $ALKS
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
MSCI Equity Indexes February 2015 Index Review
Business Wire - Wed Feb 11, 4:45PM CST
MSCI Inc. (NYSE:MSCI), a leading provider of investment decision support tools worldwide, including indexes, portfolio risk and performance analytics and ESG data and research, announced today the results of the February 2015 Quarterly Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value and Growth Indexes, the MSCI Frontier Markets and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI Pan-Euro and MSCI Euro Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index and the MSCI China A Indexes. All changes will be implemented as of the close of February 27, 2015. These changes have been posted on the Index Review web page on MSCI's web site at http://www.msci.com/products/indexes/size/sta...eview.html.
MSCI: 57.20 (unch), ALKS: 71.40 (-1.89)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS
at The Street - Wed Feb 11, 5:00AM CST
Cramer says Hasbro is the clear winner in toys and Spirit is his favorite airline stock.
HAS: 62.74 (+0.58), SAVE: 79.32 (-0.80), GM: 37.62 (-0.40), ALKS: 71.40 (-1.89)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis
Business Wire - Mon Feb 09, 6:00AM CST
---- Company Plans to Initiate Pivotal Development Program for Twice-Daily Candidate in 2015 --
ALKS: 71.40 (-1.89)
Shares of ALKS Up 19.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 9:24AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 2 months, Alkermes has returned 19.56% as of today's recent price of $69.24.
ALKS: 71.40 (-1.89)
Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences
Business Wire - Tue Feb 03, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 17th Annual BIO CEO & Investor Conference on Tuesday, Feb. 10, 2015, at 10:00 a.m. EST (3:00 p.m. GMT) from the Waldorf Astoria Hotel in New York City. In addition, Alkermes will webcast a live fireside chat, featuring Richard Pops, at the Leerink 2015 Global Healthcare Conference on Wednesday, Feb. 11, 2015, at 10:40 a.m. EST (3:40 p.m. GMT), also from the Waldorf Astoria Hotel in New York City. These presentations may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 71.40 (-1.89)
How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products
PR Newswire - Tue Feb 03, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (NASDAQ: ALGN), Alimera (NASDAQ: ALIM), Alkermes (NASDAQ: ALKS), Alliance HealthCare Services, (NASDAQ: AIQ), and Allied Healthcare Products (NASDAQ: AHPI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALGN: 56.90 (-0.34), ALIM: 5.16 (unch), AHPI: 1.56 (unch), ALKS: 71.40 (-1.89), AIQ: 24.99 (+0.27)
This Could Be Game-Changing News in the Battle Against Multiple Sclerosis
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 01, 8:12AM CST
Source: Flickr user Dominik Golenia. For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug...
BIIB: 391.66 (-0.45), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ALKS: 71.40 (-1.89), NVS: 102.20 (-0.17)
FDA clears abuse-deterrent formulation of Zohydro
Seeking Alpha - at Seeking Alpha - Sat Jan 31, 11:35AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Alkermes Shares Up 24.7% Since SmarTrend's Buy Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Jan 29, 4:59PM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 1 month, Alkermes has returned 24.66% as of today's recent price of $72.19.
ALKS: 71.40 (-1.89)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:32AM CST
Alkermes plc (ALKS) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ALXN: 182.29 (+6.02), ALKS: 71.40 (-1.89)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 4:36PM CST
SCCO: 30.43 (+0.30), FLML: 14.15 (+0.15), GDP: 3.58 (+0.29), PBF: 30.18 (+0.27), DGAZ: 7.10 (-0.49), IAG: 2.23 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ALKS: 71.40 (-1.89), XOMA: 3.41 (-0.01)
Alkermes Shares Up 15.6% Since SmarTrend's Buy Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Jan 15, 11:11AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 4 weeks, Alkermes has returned 15.58% as of today's recent price of $66.93.
ALKS: 71.40 (-1.89)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), ALKS: 71.40 (-1.89), XNPT: 6.69 (-0.21)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
MSCI Equity Indexes February 2015 Index Review
Business Wire - Wed Feb 11, 4:45PM CST
MSCI Inc. (NYSE:MSCI), a leading provider of investment decision support tools worldwide, including indexes, portfolio risk and performance analytics and ESG data and research, announced today the results of the February 2015 Quarterly Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value and Growth Indexes, the MSCI Frontier Markets and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI Pan-Euro and MSCI Euro Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index and the MSCI China A Indexes. All changes will be implemented as of the close of February 27, 2015. These changes have been posted on the Index Review web page on MSCI's web site at http://www.msci.com/products/indexes/size/sta...eview.html.
MSCI: 57.20 (unch), ALKS: 71.40 (-1.89)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS
at The Street - Wed Feb 11, 5:00AM CST
Cramer says Hasbro is the clear winner in toys and Spirit is his favorite airline stock.
HAS: 62.74 (+0.58), SAVE: 79.32 (-0.80), GM: 37.62 (-0.40), ALKS: 71.40 (-1.89)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis
Business Wire - Mon Feb 09, 6:00AM CST
---- Company Plans to Initiate Pivotal Development Program for Twice-Daily Candidate in 2015 --
ALKS: 71.40 (-1.89)
Shares of ALKS Up 19.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 9:24AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 2 months, Alkermes has returned 19.56% as of today's recent price of $69.24.
ALKS: 71.40 (-1.89)
Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences
Business Wire - Tue Feb 03, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 17th Annual BIO CEO & Investor Conference on Tuesday, Feb. 10, 2015, at 10:00 a.m. EST (3:00 p.m. GMT) from the Waldorf Astoria Hotel in New York City. In addition, Alkermes will webcast a live fireside chat, featuring Richard Pops, at the Leerink 2015 Global Healthcare Conference on Wednesday, Feb. 11, 2015, at 10:40 a.m. EST (3:40 p.m. GMT), also from the Waldorf Astoria Hotel in New York City. These presentations may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 71.40 (-1.89)
How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products
PR Newswire - Tue Feb 03, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (NASDAQ: ALGN), Alimera (NASDAQ: ALIM), Alkermes (NASDAQ: ALKS), Alliance HealthCare Services, (NASDAQ: AIQ), and Allied Healthcare Products (NASDAQ: AHPI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALGN: 56.90 (-0.34), ALIM: 5.16 (unch), AHPI: 1.56 (unch), ALKS: 71.40 (-1.89), AIQ: 24.99 (+0.27)
This Could Be Game-Changing News in the Battle Against Multiple Sclerosis
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 01, 8:12AM CST
Source: Flickr user Dominik Golenia. For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug...
BIIB: 391.66 (-0.45), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ALKS: 71.40 (-1.89), NVS: 102.20 (-0.17)
FDA clears abuse-deterrent formulation of Zohydro
Seeking Alpha - at Seeking Alpha - Sat Jan 31, 11:35AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Alkermes Shares Up 24.7% Since SmarTrend's Buy Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Jan 29, 4:59PM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 1 month, Alkermes has returned 24.66% as of today's recent price of $72.19.
ALKS: 71.40 (-1.89)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:32AM CST
Alkermes plc (ALKS) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ALXN: 182.29 (+6.02), ALKS: 71.40 (-1.89)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 4:36PM CST
SCCO: 30.43 (+0.30), FLML: 14.15 (+0.15), GDP: 3.58 (+0.29), PBF: 30.18 (+0.27), DGAZ: 7.10 (-0.49), IAG: 2.23 (-0.08), REXX: 5.08 (+0.13), SFUN: 6.74 (-0.01), ALKS: 71.40 (-1.89), XOMA: 3.41 (-0.01)
Alkermes Shares Up 15.6% Since SmarTrend's Buy Recommendation (ALKS)
Comtex SmarTrend(R) - Thu Jan 15, 11:11AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on December 19th, 2014 at $57.91. In approximately 4 weeks, Alkermes has returned 15.58% as of today's recent price of $66.93.
ALKS: 71.40 (-1.89)
XenoPort Prepping For Key Data In 2015
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:59PM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), ALKS: 71.40 (-1.89), XNPT: 6.69 (-0.21)
